Compare DexCom, Inc. (DXCM) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Schwab US Large Cap Growth ETF — how do they compare? DexCom, Inc. trades at $72.58 (market cap $28.06B), while Schwab US Large Cap Growth ETF trades at $34.59. The key difference: Schwab US Large Cap Growth ETF is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals.
| DXCM | SCHG | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | Sector/Thematic |
52-Week High | $89.53 | $35.30 |
52-Week Low | $54.84 | $28.10 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
SCHG trades at $34.74, up 0.46% with a bullish technical outlook supported by moving averages. The ETF offers concentrated exposure to large-cap growth stocks, particularly in technology and AI sectors, with top holdings including Nvidia, Apple, and Microsoft. Recent news highlights AI-driven growth potential but notes high concentration risks.
Outlook is cautiously optimistic given AI investment tailwinds, but elevated valuations and interest rate sensitivity pose risks. The fund's performance hinges on mega-cap tech stocks, making it volatile during market shifts. Diversification benefits are limited due to heavy top-10 holdings weighting.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
